On July 13, Shanghai Tianwu Technology Co., Ltd., an AI-driven protein R&D platform company, announced the completion of an A++ round of financing of hundreds of millions of yuan. This round of financing was co-led by Shanghai SDIC and SDIC Innovation, followed by Jujie Microfibre, Ningbo Yongyuan Xinglun Junjin Venture Capital, Jinjing Xinyan, Futeng Capital, and Caixin Capital, and the old shareholders Qiming Venture Capital, Yonghua Investment, Jinshajiang Joint Capital Runpu Medical Fund, Materia Medica Capital, and Shanghai Science and Technology Innovation Fund. This round of financing will mainly be used for artificial intelligence technology iteration, including the continuous development and iterative upgrade of the company's core product, the “wet and dry” protein research intelligent MatWingVenus™, and accelerate the large-scale application of AI-driven protein design capabilities in the fields of circular economy, innovative drugs, big health, pharmaceutical consumables, etc., and further promote the achievements of AI for Science from laboratories to industrialization.

On July 13, Shanghai Tianwu Technology Co., Ltd., an AI-driven protein R&D platform company, announced the completion of an A++ round of financing of hundreds of millions of yuan. This round of financing was co-led by Shanghai SDIC and SDIC Innovation, followed by Jujie Microfibre, Ningbo Yongyuan Xinglun Junjin Venture Capital, Jinjing Xinyan, Futeng Capital, and Caixin Capital, and the old shareholders Qiming Venture Capital, Yonghua Investment, Jinshajiang Joint Capital Runpu Medical Fund, Materia Medica Capital, and Shanghai Science and Technology Innovation Fund. This round of financing will mainly be used for artificial intelligence technology iteration, including the continuous development and iterative upgrade of the company's core product, the “wet and dry” protein research intelligent MatWingVenus™, and accelerate the large-scale application of AI-driven protein design capabilities in the fields of circular economy, innovative drugs, big health, pharmaceutical consumables, etc., and further promote the achievements of AI for Science from laboratories to industrialization.